MARKET

AEMD

AEMD

Aethlon Med
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.730
-0.070
-3.89%
After Hours: 1.740 +0.01 +0.58% 19:41 01/18 EST
OPEN
1.820
PREV CLOSE
1.800
HIGH
1.820
LOW
1.720
VOLUME
75.40K
TURNOVER
--
52 WEEK HIGH
12.49
52 WEEK LOW
1.450
MARKET CAP
26.64M
P/E (TTM)
-2.6562
1D
5D
1M
3M
1Y
5Y
Here's Why We're Not Too Worried About Aethlon Medical's (NASDAQ:AEMD) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Simply Wall St. · 11/30/2021 09:32
AEMD: Strong balance sheet, expanded management team & new CRO relationship expected to facilitate clinical efforts
By M. Marin NASDAQ:AEMD READ THE FULL AEMD RESEARCH REPORT
Benzinga · 11/17/2021 11:20
Watching Aethlon Medical Shares; Zacks Sets $8 Price Target
https://s27.q4cdn.com/906368049/files/News/2021/Zacks_SCR_Research_11122021_AEMD_Marin.pdf
Benzinga · 11/12/2021 18:11
Aethlon Medical Q2 EPS $(0.13) Beats $(0.15) Estimate, Sales $131.97K Miss $190.00K Estimate
Aethlon Medical (NASDAQ:AEMD) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.15) by 13.33 percent. This is a 13.33 percent increase over losses of $(0.15) per share from
Benzinga · 11/09/2021 22:49
Aethlon Medical's Return On Capital Employed Insights
According to data from Benzinga Pro, during Q1, Aethlon Medical's (NASDAQ:AEMD) reported sales totaled $131.97 thousand. Despite a 7.34% increase in earnings, the company posted a loss of $2.10 million.
Benzinga · 11/09/2021 16:21
Aethlon Medical FQ2 2022 Earnings Preview
Aethlon Medical (NASDAQ:AEMD) is scheduled to announce FQ2 earnings results on Tuesday, November 9th, after market close. The consensus EPS Estimate is -$0.15 and the consensus Revenue Estimate is $0.18M
Seekingalpha · 11/08/2021 22:35
Aethlon Medical Granted Worldwide Patent Titled 'DEVICES AND METHODS FOR TREATING A CORONAVIRUS INFECTION AND SYMPTOMS THEREOF'
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021211351&_cid=P12-KV1034-59670-1
Benzinga · 10/21/2021 13:56
BRIEF-Aethlon Medical Inc Files For Stock Shelf Of Up To $60 Million
reuters.com · 09/30/2021 17:29
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AEMD. Analyze the recent business situations of Aethlon Med through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average AEMD stock price target is 9.33 with a high estimate of 11.00 and a low estimate of 8.00.
High11.00
Average9.33
Low8.00
Current 1.730
EPS
Actual
Estimate
-0.16-0.12-0.08-0.04
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Institutional Holdings
Institutions: 33
Institutional Holdings: 1.22M
% Owned: 7.92%
Shares Outstanding: 15.40M
TypeInstitutionsShares
Increased
5
118.64K
New
5
208.50K
Decreased
4
21.27K
Sold Out
6
53.75K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
-2.27%
Healthcare Equipment & Supplies
-2.25%
Key Executives
Non-Executive Chairman/Independent Director
Edward Broenniman
Chief Executive Officer/Director
Charles Fisher
Chief Financial Officer/Senior Vice President - Finance/Secretary
James Frakes
Senior Vice President/Director
Guy Cipriani
Other
Steven Larosa
Independent Director
Sabrina Johnson
Independent Director
Chetan Shah
No Data
About AEMD
Aethlon Medical, Inc. (Aethlon) is a medical technology company, which is focused on developing products to diagnose and treat life and organ threatening diseases. The Company operates through two segments: Aethlon and ESI. The Aethlon segment represents its therapeutic business activities. The ESI segment represents its diagnostic business activities. The Company's product, Aethlon Hemopurifier is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. The Aethlon Hemopurifie is designed for the single-use removal of exosomes and life-threatening viruses from the human circulatory system. In cancer, the Aethlon Hemopurifier is designed to deplete the presence of circulating tumor-derived exosomes that promote immune suppression, seed the spread of metastasis. The Company, through its subsidiary Exosome Sciences, Inc. (ESI) is developing exosome-based biomarkers in patients with, or at risk for, a number of cancers.

Webull offers kinds of Aethlon Medical, Inc. stock information, including NASDAQ:AEMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AEMD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AEMD stock methods without spending real money on the virtual paper trading platform.